Kenya Advances Plans for First Biopharma Manufacturing and Life Sciences Park
Key Points
- Plans for Kenya's first biopharma and life sciences manufacturing park at Konza Technopolis have moved to feasibility assessment, funded by a Swedfund grant and led by Apifa Biotech with the Technopolis Development Authority.
- Jones Lang LaSalle and IQVIA have been appointed to assess technical, commercial, investment and roadmap requirements after Treasury approval in April 2026.
- The park aims to expand domestic production of medicines, APIs and medical consumables, supporting Kenya's goal to manufacture at least 50% of essential health products domestically.
Plans to establish Kenya’s first dedicated biopharmaceutical and life sciences manufacturing park have moved into the feasibility assessment stage, following grant funding from Swedish development finance institution Swedfund International. The proposed facility will be developed at Konza Technopolis through a public-private partnership involving Kenyan pharmaceutical company Apifa Biotech and the Technopolis Development Authority. The initiative is intended to expand domestic manufacturing of medicines, active pharmaceutical ingredients (APIs) and medical consumables while reducing Kenya’s dependence on imported pharmaceutical products.
The National Treasury approved the project to advance into the development phase in April 2026. A consortium comprising global real estate and investment advisory firm Jones Lang LaSalle (JLL) and healthcare analytics company IQVIA has now been appointed to conduct the feasibility study.
With support from Swedfund’s grant, the assessment will examine the proposed park’s technical and infrastructure requirements, commercial viability, investment structure and development roadmap. The findings will help establish the framework for moving the project toward implementation and attracting additional private-sector investment.
John Paul Okwiri, CEO of the Technopolis Development Authority, says the project represents an important step in establishing Konza as a regional destination for biotechnology research and pharmaceutical manufacturing. He notes that expanding domestic production capacity could help shift Kenya away from its current reliance on imported medicines.
Elsa Ekblom, Health Sector Lead at Swedfund’s Project Accelerator, said the funding will support the preliminary work needed to advance the development and establish a pathway for long-term investment in Kenya’s life sciences industry.
Apifa Biotech, a Kenyan-registered subsidiary of API for Africa (APIFA), will lead the design, development and financing of the proposed facility. The company focuses on expanding local production of APIs and essential medicines.
The development is aligned with Kenya’s national ambitions to manufacture at least 50% of its essential health products domestically. It also supports the African Union’s broader objective of meeting 60% of the continent’s health product requirements through local manufacturing by 2040.
Once established, the Biopharma Life Sciences Park is expected to provide shared infrastructure for pharmaceutical manufacturers, research organizations, technology companies and investors. The model is intended to encourage collaboration across the life sciences sector while creating an environment for companies to expand production and develop new capabilities.
Visit www.konza.org.
Total Page Views: 1

















